# Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal

> **NCT01843452** · PHASE2 · TERMINATED · sponsor: **Centre Hospitalier Universitaire Vaudois** · enrollment: 8 (actual)

## Conditions studied

- Carcinoma of Anal Canal

## Interventions

- **RADIATION:** RADIOTHERAPY
- **BIOLOGICAL:** PANITUMUMAB
- **DRUG:** MITOMYCIN
- **DRUG:** CAPECITABINE

## Key facts

- **NCT ID:** NCT01843452
- **Lead sponsor:** Centre Hospitalier Universitaire Vaudois
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Poor recruitment
- **Last updated:** 2016-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01843452

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01843452, "Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01843452. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*